
Sign up to save your podcasts
Or
Frontotemporal lobar degeneration (FTLD) is one of the most common causes of dementia in individuals under the age of 60, yet it remains lesser known and often misunderstood. From the early symptoms to the challenges of diagnosis and treatment, FTLD presents unique hurdles for clinicians, researchers and families alike. Joining the podcast to discuss this complex disease is Dr. Brad Boeve, principal investigator of the ALLFTD study, a major national research effort aimed at identifying biomarkers and clinical tools to improve early detection of FTLD and prepare for future treatment trials.
Guest: Brad Boeve, MD, neurologist, Department of Neurology and Center for Sleep Medicine, professor of neurology, Division of Behavioral Neurology, Mayo Clinic, co-director, Mayo Clinic Alzheimer’s Disease Research Center, principal investigator, ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) research study
Are you a clinician interested in receiving continuing education (CE) credits for listening to this episode? Find credit designation information, disclosures and evaluation information on our website and on the UW–Madison Interprofessional Continuing Education Partnership (ICEP) website. The accreditation for this course expires 8/12/2026. After this date, you will no longer be able to access the course or claim credit.
Learn more about Dr. Boeve and his research at his profile on the Mayo Clinic website.
Listen to our episode with Dr. Wolk, “LATE, Explained,” mentioned by Dr. Chin at 10:12 on our website.
Visit the Association for Frontotemporal Degeneration (AFTD) website, mentioned by Dr. Boeve at 21:59.
Visit the CurePSP website mentioned by Dr. Boeve at 22:21.
Find transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
4.6
132132 ratings
Frontotemporal lobar degeneration (FTLD) is one of the most common causes of dementia in individuals under the age of 60, yet it remains lesser known and often misunderstood. From the early symptoms to the challenges of diagnosis and treatment, FTLD presents unique hurdles for clinicians, researchers and families alike. Joining the podcast to discuss this complex disease is Dr. Brad Boeve, principal investigator of the ALLFTD study, a major national research effort aimed at identifying biomarkers and clinical tools to improve early detection of FTLD and prepare for future treatment trials.
Guest: Brad Boeve, MD, neurologist, Department of Neurology and Center for Sleep Medicine, professor of neurology, Division of Behavioral Neurology, Mayo Clinic, co-director, Mayo Clinic Alzheimer’s Disease Research Center, principal investigator, ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) research study
Are you a clinician interested in receiving continuing education (CE) credits for listening to this episode? Find credit designation information, disclosures and evaluation information on our website and on the UW–Madison Interprofessional Continuing Education Partnership (ICEP) website. The accreditation for this course expires 8/12/2026. After this date, you will no longer be able to access the course or claim credit.
Learn more about Dr. Boeve and his research at his profile on the Mayo Clinic website.
Listen to our episode with Dr. Wolk, “LATE, Explained,” mentioned by Dr. Chin at 10:12 on our website.
Visit the Association for Frontotemporal Degeneration (AFTD) website, mentioned by Dr. Boeve at 21:59.
Visit the CurePSP website mentioned by Dr. Boeve at 22:21.
Find transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
288 Listeners
1,713 Listeners
43,448 Listeners
12,625 Listeners
283 Listeners
3,370 Listeners
5,020 Listeners
7,991 Listeners
181 Listeners
4,372 Listeners
14,309 Listeners
28,567 Listeners
41,407 Listeners
367 Listeners
302 Listeners